ImPassion130 Trial Outcomes

ImPassion130 Trial Outcomes

obr

11 months
192 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center shares the results of ImPassion130, a phase III study adding atezolizumab to the 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative breast cancer (TNBC).
Up Next Autoplay